Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice

Diabetes

Volumn 62, Issue 9, 2013, Pages 3170-3179

  Tamura, Yukinori ^a   Kawao, Naoyuki ^a   Okada, Kiyotaka ^a   Yano, Masato ^a   Okumoto, Katsumi ^a   Matsuo, Osamu ^a   Kaji, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; MESSENGER RNA; OSTEOCALCIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOZOCIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOZOTOCIN INDUCED BONE LOSS; TIBIA; ANIMAL; BONE DENSITY; CELL CULTURE; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE DENSITY; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; LIVER; MALE; MICE; MICE, KNOCKOUT; OSTEOBLASTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX FACTORS; STREPTOZOCIN;

EID: 84887392639     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1552     Document Type: Article

References (37)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007;18:427-444
2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505
3. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007;22:1317-1328
4. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 2010;20: 683-690
5. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes 2011;2: 41-48
6. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007;102:1343-1357
7. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004;91:861-872
8. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010;87:407-416
9. Oishi K, Ohkura N, Kasamatsu M, et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004;114:129-135
10. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004; 53:336-346
11. Czekay RP, Wilkins-Port CE, Higgins SP, et al. PAI-1: an integrator of cell signaling and migration. Int J Cell Biol 2011;2011:562481
12. Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G. Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 2000;15:1510-1516
13. Chen X, Larson CS, West J, Zhang X, Kaufman DB. In vivo detection of extrapancreatic insulin gene expression in diabetic mice by bio-luminescence imaging. PLoS ONE 2010;5:e9397
14. Watkins CC, Sawa A, Jaffrey S, et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000;106:803
15. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007; 39:871-875
16. Hisa I, Inoue Y, Hendy GN, et al. Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway. J Biol Chem 2011; 286:9787-9796
17. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine 2012;41:58-69
18. Wang W, Zhang X, Zheng J, Yang J. High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 2010;338:115-122
19. Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res 1989;4:853-862
20. Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem Funct 2010;28:334-341
21. Follak N, Klöting L, Wolf E, Merk H. Delayed remodeling in the early period of fracture healing in spontaneously diabetic BB/OK rats depending on the diabetic metabolic state. Histol Histopathol 2004;19:473-486
22. Follak N, Klöting I, Merk H. Influence of diabetic metabolic state on fracture healing in spontaneously diabetic rats. Diabetes Metab Res Rev 2005;21:288-296
23. Koroglu BK, Kiris F, Ersoy IH, et al. Relation of leptin, adiponectin and insulin resistance to bone mineral density in type 2 diabetic post-menopausal women. Endokrynol Pol 2011;62:429-435
24. Cloos C, Wahl P, Hasslacher C, et al. Urinary glycosylated, free and total pyridinoline and free and total deoxypyridinoline in diabetes mellitus. Clin Endocrinol (Oxf) 1998;48:317-323
25. Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 1998;11:413-419
26. Herrero S, Calvo OM, García-Moreno C, et al. Low bone density with normal bone turnover in ovariectomized and streptozotocin-induced diabetic rats. Calcif Tissue Int 1998;62:260-265
27. Verhaeghe J, Thomsen JS, van Bree R, van Herck E, Bouillon R, Mosekilde L. Effects of exercise and disuse on bone remodeling, bone mass, and biomechanical competence in spontaneously diabetic female rats. Bone 2000;27:249-256
28. Rosen CJ, Ackert-Bicknell C, Rodriguez JP, Pino AM. Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr 2009;19:109-124
29. Akune T, Ohba S, Kamekura S, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-855
30. Crandall DL, Quinet EM, El Ayachi S, et al. Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol 2006;26:2209-2215
31. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 2006;103:9232-9237
32. DiMusto PD, Lu G, Ghosh A, et al. Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model. Am J Physiol Heart Circ Physiol 2012;302:H1378-H1386
33. Karasik D, Ferrari SL. Contribution of gender-specific genetic factors to osteoporosis risk. Ann Hum Genet 2008;72:696-714
34. Wallace JM, Rajachar RM, Chen XD, et al. The mechanical phenotype of biglycan-deficient mice is bone-and gender-specific. Bone 2006;39:106-116
35. Nielsen KL, Allen MR, Bloomfield SA, et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. J Bone Miner Res 2003;18:2152-2158
36. Olivares-Navarrete R, Hyzy SL, Chaudhri RA, Zhao G, Boyan BD, Schwartz Z. Sex dependent regulation of osteoblast response to implant surface properties by systemic hormones. Biol Sex Differ 2010;1:4
37. Daci E, Everts V, Torrekens S, et al. Increased bone formation in mice lacking plasminogen activators. J Bone Miner Res 2003;18:1167-1176